» Articles » PMID: 39941298

The Promise of Infrared Spectroscopy in Liquid Biopsies for Solid Cancer Detection

Overview
Specialty Radiology
Date 2025 Feb 13
PMID 39941298
Authors
Affiliations
Soon will be listed here.
Abstract

Attenuated total reflection-Fourier transform infrared (ATR-FTIR) spectroscopy has shown significant promise in the context of liquid biopsy, offering a potential tool for cancer diagnostics. Unlike traditional tissue biopsies, which may not fully capture the clonal heterogeneity of tumors, liquid biopsy reflects the dynamic state of the disease and its progression more comprehensively. Biofluids such as serum and plasma are low-cost, minimally invasive diagnostic media with well-established clinical uses. This review assesses the use of ATR-FTIR spectroscopy to detect biochemical changes in biofluids linked to various malignancies, including breast, ovarian, endometrial, prostate, bladder, kidney, pancreatic, colorectal, hepatic, esophageal, gastric, lung, and brain cancers. While ATR-FTIR offers the advantages of rapid, minimally invasive detection and real-time disease monitoring, its integration into clinical practice faces challenges, particularly in terms of reproducibility due to variability in sample preparation, spectral acquisition, and data processing. The translation of ATR-FTIR into routine diagnostics will require validation through large-scale cohort studies and multicenter trials to ensure its clinical reliability and effectiveness.

References
1.
Lima K, Gajjar K, Martin-Hirsch P, Martin F . Segregation of ovarian cancer stage exploiting spectral biomarkers derived from blood plasma or serum analysis: ATR-FTIR spectroscopy coupled with variable selection methods. Biotechnol Prog. 2015; 31(3):832-9. DOI: 10.1002/btpr.2084. View

2.
Gray E, Butler H, Board R, Brennan P, Chalmers A, Dawson T . Health economic evaluation of a serum-based blood test for brain tumour diagnosis: exploration of two clinical scenarios. BMJ Open. 2018; 8(5):e017593. PMC: 5988134. DOI: 10.1136/bmjopen-2017-017593. View

3.
Yan Y, Guo Q, Wang F, Adhikari R, Zhu Z, Zhang H . Cell-Free DNA: Hope and Potential Application in Cancer. Front Cell Dev Biol. 2021; 9:639233. PMC: 7938321. DOI: 10.3389/fcell.2021.639233. View

4.
Delgado-Lopez P, Rinones-Mena E, Corrales-Garcia E . Treatment-related changes in glioblastoma: a review on the controversies in response assessment criteria and the concepts of true progression, pseudoprogression, pseudoresponse and radionecrosis. Clin Transl Oncol. 2017; 20(8):939-953. DOI: 10.1007/s12094-017-1816-x. View

5.
Crosbie E, Kitson S, McAlpine J, Mukhopadhyay A, Powell M, Singh N . Endometrial cancer. Lancet. 2022; 399(10333):1412-1428. DOI: 10.1016/S0140-6736(22)00323-3. View